利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

15 条记录 (耗时 0.032 秒)

    RANDOMIZATION HONORING METHODS TO ASSESS THE SIGNIFICANCE OF INTERVENTIONS ON OUTCOMES IN DISORDERS
    6.
    发明申请
    RANDOMIZATION HONORING METHODS TO ASSESS THE SIGNIFICANCE OF INTERVENTIONS ON OUTCOMES IN DISORDERS 有权

    公开(公告)号：US20220130500A1

    公开(公告)日：2022-04-28

    申请号：US17508182

    申请日：2021-10-22

    申请人： TONIX PHARMACEUTICALS HOLDING CORP. ,  TONIX PHARMACEUTICALS INC.

    发明人： Seth Lederman ,  Philip B. Stark ,  Ben Vaughn

    IPC分类号： G16H10/20 ,  G06F17/18

    摘要： Systems and methods for an analysis of clinical trial data using randomization tests that honors the randomized design of the clinical trial are provided herein. In particular, a non-parametric analyzer implementing randomization tests and associated methods for analyzing clinical data is provided. The non-parametric analyzer receives clinical trial data comprising a data structure containing data corresponding to subjects in the clinical trial, where the subjects have been organized into treatment groups, including at least one control group. The non-parametric analyzer generates multiple treatment allocations of the data structure by reorganizing, at random, the subjects along with corresponding data to generate further groups. In some embodiments, the non-parametric analyzer determines the statistical significance based on an overall probability and the multiple allocations of the data structure. The overall probability may be generated via a combination analysis for comparing test statistics between groups of the data structure and the multiple allocations.

    CYCLOBENZAPRINE TREATMENT FOR ALCOHOL USE DISORDER
    9.
    发明公开
    CYCLOBENZAPRINE TREATMENT FOR ALCOHOL USE DISORDER 审中-公开

    公开(公告)号：US20240009146A1

    公开(公告)日：2024-01-11

    申请号：US18037815

    申请日：2021-11-19

    申请人： Tonix Pharmaceuticals Holding Corp.

    发明人： Seth Lederman ,  Greg M. Sullivan

    IPC分类号： A61K31/137

    CPC分类号： A61K31/137

    摘要： The present disclosure provides a method for treating alcohol use disorder (AUD) and associated symptoms to a subject in need thereof by administering to the subject a pharmaceutical composition comprising a therapeutically effective amount of cyclobenzaprine or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier. The pharmaceutically acceptable salt comprises a cyclobenzaprine acid salt.